2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration. (20th October 2022)
- Record Type:
- Journal Article
- Title:
- 2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration. (20th October 2022)
- Main Title:
- 2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration
- Authors:
- Fernebro, Josefin
Corvigno, Sara
Mezheieusky, Arthur
Karlsson, Josefin Severin
Fuente, Laura Martin De La
Westbom-Fremer, Sofia M
Carlson, Joseph
Kannisto, Paivi M
Hedenfalk, Ingrid M
Malander, Susanne M
Östman, Arne
Dahlstrand, Hanna - Abstract:
- Abstract : Introduction/Background: Tumor biology studies have implied that fibroblasts act as negative regulators of immune cell function in cancer. We investigated the impact of FAP-positive cells in high-grade serous ovarian cancer (HGSC) in relation to CD8 expression. Methodology: A discovery cohort (N=113) of HGSC was subjected to immunohistochemistry (IHC) of FAP and CD8. Marker status was correlated with overall survival (OS) and progression-free survival (PFS). Findings were confirmed in a validation cohort (N=121) and in public available datasets (TCGA and GSE9891). Results: We confirmed previous findings that high density of CD8+ cells in HGSC is associated with longer OS compared to low density (HR 0.55; 95% CI 0.33–0.85; p=0.008). In the discovery cohort high intensity of FAP was associated with shorter median PFS in cases with high density of stromal CD8+ cells (11.4 versus 18.6 months) compared to low intensity of FAP (p=0.007). In contrast, high intensity of FAP was not associated with PFS in cases with low density of CD8+ cells. In the validation cohort, high intensity of FAP in the patients with high density of stromal CD8+ cells was associated with shorter OS compared to low intensity of FAP (p=0.01). This association was not seen in the cases with low density of CD8+ cells. The association between high FAP expression and poor outcome in the high density CD8+ group was confirmed in two independent gene-expression data sets, with a shorter PFS in the TCGAAbstract : Introduction/Background: Tumor biology studies have implied that fibroblasts act as negative regulators of immune cell function in cancer. We investigated the impact of FAP-positive cells in high-grade serous ovarian cancer (HGSC) in relation to CD8 expression. Methodology: A discovery cohort (N=113) of HGSC was subjected to immunohistochemistry (IHC) of FAP and CD8. Marker status was correlated with overall survival (OS) and progression-free survival (PFS). Findings were confirmed in a validation cohort (N=121) and in public available datasets (TCGA and GSE9891). Results: We confirmed previous findings that high density of CD8+ cells in HGSC is associated with longer OS compared to low density (HR 0.55; 95% CI 0.33–0.85; p=0.008). In the discovery cohort high intensity of FAP was associated with shorter median PFS in cases with high density of stromal CD8+ cells (11.4 versus 18.6 months) compared to low intensity of FAP (p=0.007). In contrast, high intensity of FAP was not associated with PFS in cases with low density of CD8+ cells. In the validation cohort, high intensity of FAP in the patients with high density of stromal CD8+ cells was associated with shorter OS compared to low intensity of FAP (p=0.01). This association was not seen in the cases with low density of CD8+ cells. The association between high FAP expression and poor outcome in the high density CD8+ group was confirmed in two independent gene-expression data sets, with a shorter PFS in the TCGA dataset and shorter PFS and OS in the GSE9891 dataset. Conclusion: The study shows a specific FAP positive fibroblast-subset of cases with poor prognosis restricted to a CD8 high density group of HGSC. Therapy targeting the immunosuppressive action of fibroblasts may be a tool to enhance the known positive prognostic effect of CD8-cells in ovarian cancer and may be explored in T-cell depended immune therapy. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 2
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 2
- Issue Display:
- Volume 32, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 2
- Issue Sort Value:
- 2022-0032-0002-0000
- Page Start:
- A411
- Page End:
- A411
- Publication Date:
- 2022-10-20
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-ESGO.880 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24562.xml